Functional polymorphisms of the leptin and leptin receptor genes are associated with longevity and with the risk of myocardial infarction and of type 2 diabetes mellitus

Funkcjonalne polimorfizmy genów leptyny i receptora leptyny korelują z długowiecznością oraz z ryzykiem zawału mięśnia serca i cukrzycy 2 typu

Małgorzata Roszkowska-Gancarz¹, Alina Kuryłowicz², Jacek Polosak⁴, ², Małgorzata Mossakowska³, Edward Franek², Monika Pużianowska-Kuźnicka¹, ²

¹Department of Geriatrics and Gerontology, Centre of Postgraduate Medical Education, Warsaw, Poland
²Department of Human Epigenetics, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
³Centenarians’ Project, International Institute of Molecular and Cell Biology, Warsaw, Poland

Abstract

Introduction: Longevity is commonly associated with good health and with delayed onset of age-related diseases with usually benign course. Leptin (LEP) significantly affects metabolism and numerous functions of the organism. To find out if extreme longevity and its phenotype are associated with genetic variants of leptin and leptin receptor (LEPR) genes, we analysed the frequencies of the −2548 G/A and +19 G/A LEP, as well as the K109R, Q223R, and K656N LEPR polymorphisms in centenarians and in control groups.

Material and methods: The frequencies of the LEP and LEPR polymorphisms were tested by restriction fragment length polymorphism in 128 centenarians, 414 young controls (Y), 226 myocardial infarction (MI) patients, and 190 type 2 diabetes mellitus (DM2) patients.

Results: The GG genotype of the −2548 G/A LEP polymorphism was significantly more common in centenarians than in the Y, MI and DM2 groups (p = 0.048, p = 0.003, p = 0.049, respectively). In addition, the AA genotype of the K109R LEPR polymorphism was significantly less frequent in centenarians than in the Y, MI, and DM2 groups (p = 0.026, p = 0.013, and p = 0.001, respectively).

Conclusions: We suggest that the leptin pathway plays a role in the regulation of longevity, possibly by modulating the risk of development of MI and of DM2. (Endokrynol Pol 2014; 65 (1): 11–16)

Key words: leptin gene (LEP); leptin receptor gene (LEPR); polymorphism; longevity; centenarians; myocardial infarction (MI); type 2 diabetes mellitus (DM2)

Streszczenie

Wstęp: Długowieczność często towarzyszy dobry stan zdrowia, opóźnione zachorowanie na „choroby związane z wiekiem”, których przebieg jest zwykle łagodny. Leptyna (LEP) znacząco wpływa na metabolizm oraz na inne funkcje organizmu. Aby sprawdzić, czy ekstremalna długowieczność i jej fenotyp są powiązane z odmianami genów leptyny i receptora leptyny (LEPR), przebadaliśmy częstość występowania polimorfizmów –2548 G/A i +19 G/A genu LEP, a także K109R, Q223R, i K656N genu LEPR w centenarach i w grupach kontrolnych.

Materiał i metody: Męscie się częstotliwość występowania polimorfizmów genn LEP i LEPR testowaliśmy metodą analizy długości fragmentów restrykcyjnych w 128 centenarach, 414 młodych kontrol (Y), 226 pacjentów z zawałem serca (MI) i 190 pacjentów z cukrzycą 2 typu (DM2).

 Wyniki: Genotyp GG polimorfizmu −2548 G/A genu LEP był znamiennie częstszy u centenarów niż w grupach Y, MI i DM2 (odpowiednio p = 0.048, p = 0.003, p = 0.049, odpowiednio). Dodatkowo, genotyp AA polimorfizmu K109R genu LEPR był znamiennie rzadszy u centenarów niż w grupach Y, MI i DM2 (odpowiednio p = 0.026, p = 0.013 i p = 0.001).

Wnioski: sugerujemy, że szlak oddziaływań leptyny bierze udział w regulowaniu długości życia, być może poprzez modulowanie ryzyka zachorowania na MI i DM2. (Endokrynol Pol 2014; 65 (1): 11–16)

Słowa kluczowe: gen leptyny (LEP); gen receptora leptyny (LEPR); polimorfizm; długowieczność; centenarius; zawał serca (MI); cukrzyca 2 typu (DM2)

This work was supported by the Polish State Committee for Scientific Research (KBN) grant, number PBZ-KBN-022/PO5/1999, and by the Polish Ministry of Science and Higher Education grant, number PBZ-MIN-9/2/2006 — K143/P01/2007/1.
The majority of published data indicate that ageing is associated with an increase in the LEP serum level [13, 14], although some reports suggest the opposite correlation [15]. Age-related hyperleptinemia correlates with resistance to LEP function on fat distribution and on insulin action [8, 16]. Hyperleptinemia and LEP resistance in elderly humans are risk factors for calcification of vascular cells [17], aggregation of platelets [18], increased oxidation of LDL particles [19], hypertension [20], obesity [21], impaired insulin signalling [22], coronary artery disease and metabolic syndrome [23], as well as stroke [24, 25], low bone density [6, 26], cancer [27] etc.

This prompted us to hypothesise that certain LEP and LEPR functional polymorphisms might extend life by lowering the risk of developing age-related diseases such as diabetes, cardiovascular disease and cancer, as well as by influencing the ageing process through modulation of metabolism and of insulin function.

To verify our hypothesis, we analysed the frequencies of the –2548 G/A, and +19 G/A LEP, as well as the K109R A/G, Q223R A/G, and K656N G/C LEPR polymorphisms in centenarians, in young persons, in myocardial infarction (MI) patients, and in type 2 diabetes mellitus (DM2) patients. The polymorphisms were selected on the basis of their proven functionality or association with the risk of development of diseases the frequency of which is increased in aged humans (see ‘Discussion’ for details).

We here present evidence that the frequency of certain LEP and LEPR polymorphisms is significantly different in centenarians and in young controls, in MI, and in DM2 patients, suggesting that the LEP axis may play a role in the regulation of longevity.

Material and methods

Study participants

A cross-sectional analysis of the LEP and LEPR genetic variants was performed in: 128 Polish centenarians never diagnosed with myocardial infarction (MI) or with type 2 diabetes mellitus (DM2) (C), 99.58-107.25 years, mean ± SD 101.11 ± 1.19 years, 112 females and 16 males — participants in the ‘PolSenior’ study of the ageing population in Poland [29].

All participants gave written informed consent for participation in the study. The study protocol was approved by the Bioethical Committee of the Medical University of Warsaw.

DNA isolation and analysis of restriction fragment length polymorphisms

Four ml blood samples were used for the isolation of the genomic DNA; this was performed using the salting-out procedure [30]. Genotyping of the selected polymorphisms in LEP and in LEPR was done by PCR amplification followed by digestion with an appropriate restriction enzyme (restriction fragment length polymorphism method — RFLP). PCR-RFLP conditions used for the analysis are shown in Table I. The Q223R polymorphism of LEPR was analysed as previously described [31]. Conditions for the analysis of the remaining polymorphisms were developed in our laboratory. The restriction fragments obtained were visualised on 2–3% agarose gels.

Statistical analysis

All analyses were performed using the Statistica software package (StatSoft, Tulsa, OK, USA). Hardy-Weinberg equilibrium and differences in genotype frequencies in the introductory analysis, as well as between the analysed age/disease groups, were checked with the chi² test. The distribution of genotypes was analysed in three models of inheritance: dominant, recessive and codominant using 2 × 2, 2 × 2, 3 × 2 contingency tables, respectively. The differences in quantitative parameters between genotypes in the C group were assessed using ad-hoc test (Kruskal-Wallis ANOVA for cholesterol or ANOVA for other parameters) and post-hoc tests (Student’s t-test for cholesterol or U Mann-Whitney test for other parameters). For all tests, the level of significance was established at 0.05.

Results

Distribution of the LEP and LEPR polymorphisms in centenarians vs. young individuals

Two polymorphisms in the leptin gene promoter (–2548 G/A, +19 G/A) and three amino acid sequence-changing polymorphisms in the leptin receptor-encoding gene (K109R A/G, Q223R A/G, K656N G/C) were studied. The frequencies of each genotype in centenarians and in young controls are shown in Table II.

Introductory analysis was performed in Y subjects. No significant sex-dependent differences in the frequencies of these polymorphisms were detected. Similarly, combined analysis of Y subjects and of C subjects showed that the distribution of the analysed polymorphisms did not differ significantly between sexes.
Next, the LEP and LEPR polymorphisms were compared in the two age groups. We found that the GG genotype of the –2548 G/A LEP polymorphism was significantly more frequent in centenarians than in young controls (43.75% vs. 33.57%, p = 0.048, OR = 1.539 [95% CI: 1.006–2.352]). The +19 G/A LEP polymorphism was similarly distributed.

The K109R LEPR polymorphism was also differently distributed among the two groups: the AA genotype was significantly less frequent in the C group than in the Y group (41.40% vs. 52.66%, p = 0.026, OR = 0.635 [95% CI: 0.417–0.967]). For the Q223R and K656N LEPR polymorphisms, no significant differences in the distribution of genotypes were observed between the groups.

**Distribution of the LEP and LEPR polymorphisms in centenarians vs. myocardial infarction patients**

The frequencies of the same polymorphisms in myocardial infarction patients (MI) are shown in Table II. We found no significant differences in the distribution of all analysed LEP polymorphisms between the MI

---

### Table I. PCR-RFLP conditions used for the analysis of the selected polymorphisms in the LEP and in the LEPR genes

<table>
<thead>
<tr>
<th>Gene</th>
<th>Polymorphism</th>
<th>Primers</th>
<th>T&lt;sub&gt;m&lt;/sub&gt; (°C)</th>
<th>PCR product (bp)</th>
<th>Restriction enzyme</th>
<th>Alleles (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEP</td>
<td>–2548 G/A</td>
<td>F: 5’TGGGTACTTATACAAACAGAATAAACA3’</td>
<td>54</td>
<td>325</td>
<td>HhaI</td>
<td>A: 325</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: 5’AAAGCAAAGACAGGCATAAAAA3’</td>
<td></td>
<td></td>
<td></td>
<td>G: 180, 145</td>
</tr>
<tr>
<td></td>
<td>+19 G/A</td>
<td>F: 5’ATGGAGCCCCGTAGGAATC3’</td>
<td>59</td>
<td>220</td>
<td>TaqI</td>
<td>G: 220</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: 5’CAGCTCCCCGTAACCTCTA3’</td>
<td></td>
<td></td>
<td></td>
<td>A: 188, 32</td>
</tr>
<tr>
<td>LEPR</td>
<td>K109R A/G</td>
<td>F: 5’CTTTGCGCTGGACTCCTC3’</td>
<td>59</td>
<td>217</td>
<td>BsuR1</td>
<td>A: 217</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: 5’AAACTAAAGAATTCTTGGTTGAAACAAATGGC3’</td>
<td></td>
<td></td>
<td></td>
<td>G: 186, 31</td>
</tr>
<tr>
<td></td>
<td>Q223R A/G</td>
<td>F: 5’ACCCCTTAACTCGGGTGCCCAAATAG3’</td>
<td>56</td>
<td>416</td>
<td>BseNI</td>
<td>A: 221, 125, 71</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: 5’AGCTAGCAAATATTTTTTGAACAAATT3’</td>
<td></td>
<td></td>
<td></td>
<td>G: 186, 31</td>
</tr>
<tr>
<td></td>
<td>K656N G/C</td>
<td>F: 5’ACTAGATGGACTGGGATATTGGAGTAAT3’</td>
<td>56</td>
<td>251</td>
<td>BstUI</td>
<td>G: 251</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R: 5’CTCCTCAAAGTAAAGTGACATTTTTCG3’</td>
<td></td>
<td></td>
<td></td>
<td>C: 231, 20</td>
</tr>
</tbody>
</table>

<sup>T<sub>m</sub> — melting temperature; F — forward; R — reverse; bp — base pairs</sup>
and Y groups. However, comparison of the C and MI groups revealed that polymorphisms of the LEP gene promoter were differentially distributed: the GG genotype of the −2548 G/A polymorphism was more frequent in centenarians than in MI patients (43.75% vs. 29.64%, \( p = 0.003 \), OR = 1.85 [95% CI: 1.18–2.89]).

No significant differences in frequencies of the K109R, Q223R and K656N LEPR polymorphisms were detected between the MI and Y groups. The AA genotype of the K109R was significantly less frequent in the C group than in the MI group (41.40% vs. 52.11%, \( p = 0.013 \), OR = 0.65 [95% CI: 0.42–1.00]). The differences in distribution of the remaining two LEPR polymorphisms in the C vs. MI groups were insignificant.

**Distribution of the LEP and LEPR polymorphisms in centenarians v. type 2 diabetes mellitus patients**

Analysis of the frequencies of the polymorphisms under study in type 2 diabetes mellitus patients (Table II) gave the following results.

The AA genotype of the −2548 G/A LEP polymorphism was significantly less frequent in the DM2 group than in the Y group (11.58% vs. 17.40%, \( p = 0.018 \), OR = 1.60 [95% CI: 0.96–2.67]). The genotypes of the +19 G/A LEPR polymorphism were not differentially distributed among these groups. Comparison of the C and DM2 groups showed that the GG genotype of the −2548 G/A LEPR polymorphism was significantly more common in centenarians (43.75% vs. 37.37%, \( p = 0.049 \), OR = 1.3 [95% CI: 0.83–2.05]). The +19 G/A polymorphism was distributed equally in the C and DM2 groups.

Analysis of the LEPR polymorphisms indicated that the AA genotype of the K109R polymorphism and the GG genotype of the K656N polymorphism were less frequent in the Y group than in the DM2 group (K109R: 52.66% vs. 58.42%, \( p = 0.029 \), OR = 0.79 [95% CI: 0.561.12]; K656N: 71.74% vs. 75.79%, \( p = 0.046 \), OR = 0.81 [95% CI: 0.54–1.20]), while the frequencies of the Q223R genotypes did not differ between these groups. The AA genotype of the K109R polymorphism was also significantly less frequent in the C group than in the DM2 group (41.40% vs. 58.42%, \( p = 0.001 \), OR = 0.50 [95% CI: 0.32–0.79], respectively). The frequencies of the remaining LEPR genotypes did not differ between these groups.

**Correlations of the LEP and LEPR polymorphisms with metabolic variables in centenarians**

The metabolic variables of the C group were as follows: body mass index (BMI) 15.3–37.4 kg/m², mean ± SD 23.6 ± 4.4 kg/m²; fasting glucose 26–315 mg/dL, mean ± SD 86.7 ± 31.8 mg/dL; insulin 5.82–586 pmol/L, mean ± SD 58.73 ± 81.18 pmol/L; total cholesterol 100–316 mg/dL, mean ± SD 195.3 ± 45.4 mg/dL; HDL cholesterol 26–136 mg/dL, mean ± SD 60.0 ± 17.7 mg/dL; triglycerides 45–436 mg/dL, mean ± SD 108.8 ± 51.4 mg/dL. Association analysis of genotypes of the LEP and LEPR polymorphisms with these metabolic measures was performed.

The Q223R LEPR polymorphism correlated with fasting glucose: carriers of the AA genotype of this polymorphism had a significantly lower mean fasting glucose level than GG homozygotes (80.12 ± 12.21 mg/dL vs. 95.75 ± 39.42 mg/dL, \( p = 0.002 \)). They also had a significantly lower mean fasting insulin level than carriers of at least one G allele (44.59 ± 78.92 pmol/L vs. 64.52 ± 87.53 pmol/L, \( p = 0.013 \)), and GG homozygotes (44.59 ± 78.92 pmol/L vs. 52.74 ± 46.91 pmol/L, \( p = 0.06 \)).

We found no significant associations between the G-2548A and G+19A LEP, as well as the K109R and K656N LEPR genotypes and BMI, fasting glucose, total cholesterol, HDL cholesterol, and triglycerides levels.

**Discussion and conclusions**

Ageing is accompanied by an increased risk of developing cardiovascular disease, cancer, diabetes, osteoporosis, sarcopenia and diseases related to immune system dysfunction. All these conditions negatively affect longevity. It is well documented that age progression is associated with an increase in the level of LEP [13, 14]; however, this rule does not seem to apply to centenarians [32]. To ascertain whether LEP signalling has an impact on extreme longevity, which is usually associated with good health and delayed occurrence of typical age-related diseases, we analysed the frequencies of the −2548 G/A and +19 G/A LEPR, as well as the K109R A/G, Q223R A/G, and K656N G/C LEPR polymorphisms in centenarians and compared them to their frequencies in young individuals, as well as in MI and in DM2 patients who were diagnosed before the age of 55. We purposely selected young MI and DM2 patients, since a genetic predisposition towards development of various diseases plays a more important role in young than in old persons and, therefore, can be more easily detected.

We found that the GG genotype of the −2548 G/A LEP promoter polymorphism is significantly more common in centenarians never diagnosed with MI or with DM2 than in young controls, and in the MI and DM2 groups. This finding seems to contrast with previously published data showing that the G allele of this polymorphism is associated with obesity [33, 34]. There are at least three potential explanations for such a discrepancy: first, obesity at a younger age might be of low importance for extreme longevity; second, this polymorphism might be a low-importance regulatory factor of longevity; third, a protective role of this geno-
type against development of MI or DM2 might prevail over its influence on obesity. This third hypothesis seems to be the most probable, since, as mentioned above, we also found that this genotype was significantly more common in the C group than in the MI and DM2 groups. In addition, overrepresentation of this genotype in the C group remains in agreement with previous findings that it is the A allele which increases the risk of development of non-small cell lung cancer, oral, prostate and breast cancers, as well as non-Hodgkin’s lymphoma [35–41]. Indeed, our centenarian study subjects rarely suffered from neoplastic disease: only two of them had cancers (uterus or thyroid), and six others had non-melanoma-type skin cancer of benign clinical course in sun-exposed skin areas.

The +19 G/A LEP promoter polymorphism, had not been extensively studied; however, available reports show that its GG and GA genotypes correlate with the risk of various cancers [38, 39, 41]. We found that it was related neither to longevity, nor to MI or DM2.

The K109R LEPR polymorphism is the next one that is associated with extreme longevity. We showed that its AA genotype is significantly less common in the C group than in the Y, MI and DM2 groups. This remains in agreement with previous findings that this genotype is associated with obesity [44] and with increased DM2 risk [45].

The presence of the Q223R LEPR G allele was previously associated with obesity [46–48]. However, the findings regarding its association with altered glucose and lipid metabolism are conflicting [48–51]. In addition, the GG genotype of this polymorphism correlates with increased risk of breast carcinoma and of oral cancer [38, 39, 41]. We showed in this work that this polymorphism is in fact not associated with longevity. Inconsistency of the available data regarding its role in morbidity makes plausible the idea that this polymorphism does not play a role in longevity regulation. Be that as it may, we should remember that the C group might not be sufficiently large to show a correlation.

While correlating metabolic parameters’ values with the LEP and LEPR genotypes, we found that centenarian carriers of the Q223R LEPR AA genotype paradoxically had a significantly lower mean fasting glucose and insulin levels compared to carriers of other genotypes.

This finding is of great importance since it has been previously found that low-normal fasting glucose levels are associated with lower risk of DM2 compared to high-normal values [52, 54]. Our results remain in agreement with those of Chin et al. and of Takahashi-Yasuno et al. [49, 50].

This study presents only preliminary data and has several limitations. First, the LEP and LEPR polymorphism frequencies were analysed only in young and in centenarian age groups, while it would have been more informative to test an additional group of intermediate age. Second, the number of centenarians, although high if compared to centenarian groups analysed in the majority of other publications, amounted to only 128; therefore, our results should be confirmed on a much larger group of centenarians of various ethnic backgrounds. Third, it could be objected that our study groups were uneven with respect to sex distribution.

This is, however, of little or no significance since our introductory analysis showed no association of the analysed polymorphisms with sex.

To sum up, we suggest that the leptin pathway could impact upon human longevity. We also suggest that this might be so, at least in part, because of the modulation of the risk of developing cardiovascular disease and type 2 diabetes mellitus.

Acknowledgments

We thank Aleksandra Szybinska, International Institute of Molecular and Cell Biology, Warsaw, Poland, Dr. Olga Turowska from the Central Hospital MSWiA, Warsaw, Poland, and Dr. Michal Ambroziak, Department of Cardiology, Medical Centre of Postgraduate Education, Warsaw, Poland, for the genomic DNAs.

References

Leptin and leptin receptor genes and longevity


38. Snoussi K, Strobsberg AD, Bouauxina N et al. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer 2006; 6: 38.


